ArticleBMC nephrology2017
Simple, readily available clinical indices predict early and late mortality among patients with ANCA-associated vasculitis.
Article in BMC nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Mortality risk and causes of death in exogenous Cushing's syndrome: a systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- Mortality risk stratification in antineutrophil cytoplasmic antibody-associated vasculitis: baseline severity, accumulated damage burden and cardio-renal vulnerability in a Chinese two-center cohort.Frontiers in medicine · 2026Article
- The Prognosis of Granulomatosis With Polyangiitis: The Risk of Relapse and Mortality Based on Baseline Clinical Manifestations, Laboratory Findings, and Disease Severity: A Retrospective Cohort Study.Health science reports · 2025Article
- Review
- Circulating GDF15 May Estimate Vasculitis Activity and Predict Poor Outcomes During the Disease Course of ANCA-Associated Vasculitis.Journal of clinical medicine · 2025Article
- Chemokine expression in sera of patients with microscopic polyangiitis and granulomatosis with polyangiitis.Scientific reports · 2024Article
- Impact of different ANCA serotypes on the long-term outcome of ANCA-associated vasculitis patients.Annals of medicine · 2023Article
- Type of ANCA May Be Indispensable in Distinguishing Subphenotypes of Different Clinical Entities in ANCA-Associated Vasculitis.Life (Basel, Switzerland) · 2022Review
- The risk factors for early mortality and end-stage renal disease in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis: experiences from a single center.Clinical and experimental medicine · 2021Article
- ANCA-Associated Vasculitis Clinical Presentation and Clinical Predictors of Relapse in Saudi Arabia.Open access rheumatology : research and reviews · 2021Article
- Clinical characteristics and outcomes in microscopic polyangiitis patients with renal involvement: a study of 124 Chinese patients.BMC nephrology · 2019Observational
- Clinical value of systemic symptoms in IgA nephropathy with ANCA positivity.Clinical rheumatology · 2018Article
- Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study.BMC nephrology · 2018Article
- Analysis of Antineutrophil Cytoplasm Antibody from 118 730 Patients in Tertiary Hospitals in Jiangxi Province, China.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe early identification of patients with ANCA-associated vasculitis (AAV) who are at increased risk for inferior clinical outcome at the time of diagnosis might help to optimize the immunosuppressive therapy. In this study we wanted to determine the predictive value of simple clinical characteristics, which may be applicable for early risk-stratification of patients with AAV.
methodsWe retrospectively analyzed the outcome of 101 consecutive patients with AAV receiving a protocolized immunosuppressive therapy. Baseline Birmingham Vasculitis Activity Score (BVAS) and non-vasculitic comorbidities were computed, then predictors of early (<90 days) and late (>90 days) mortality, infectious death, relapse and end stage kidney disease (ESKD) were evaluated.
resultsThe baseline comorbidity score independently predicted early mortality (HR 1.622, CI 1.006-2.614), and showed association with infectious mortality (HR 2.056, CI 1.247-3.392). Patients with BVAS at or above median (=21) had worse early mortality in univariable analysis (HR 3.57, CI 1.039-12.243) (p = 0.031), and had more frequent relapses (p = 0.01) compared to patients with BVAS below median.
conclusionsAssessing baseline comorbidities, beside clinical indices characterizing the severity and extension of AAV, might help clinicians in risk-stratification of patients. Future prospective studies are needed to investigate whether therapies based on risk-stratification could improve both short term and long term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.